What the label lists and what reports show
Chorionic gonadotropin side effects
Chorionic gonadotropin's FDA label lists its adverse reactions in its own words. FAERS holds 547 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is ovarian hyperstimulation syndrome (129 reports).
- No generic listed
Check it at the source: the chorionic gonadotropin FDA label on DailyMed (effective April 11, 2025); the FDA FAERS public dashboard.
What does the label list?
From the label: adverse reactionsHeadache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia and pain at the site of injection.
Source: FDA drug label, Fresenius Kabi USA, LLC, effective April 11, 2025 (SPL set f93b2baa-03ac-4650-b35a-20b818d712d6), via openFDA; the full label on DailyMed
What do FAERS reports show?
547 reports list chorionic gonadotropin among the medicines taken, each a report of something that happened, not proof the medicine caused it; 26 are coded as a death and 251 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 20 reactions below, 2 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Chorionic gonadotropin: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions